MedTrace Logo

The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea

NCT03081676 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-06-27

No results posted yet for this study

Summary

The most prevalent monogenetic diabetic subtype is named maturity onset diabetes of the young type (MODY3) or hepatocyte nuclear factor 1α (HNF1A)-diabetes. The aim of this study is to evaluate the effects of supra-physiological levels of GIP and GLP-1, respectively, on insulin and glucagon secretion at fasting plasma glucose (FPG) and "post-prandial" PG levels (1.5 × FPG) in patients with HNF1A-diabetes and matched healthy controls treated with or without a low dose of glimepiride (sulphonylurea). In addition, we will evaluate the maximal insulin and glucagon secretory capacity in both groups.

Conditions

  • Maturity-Onset Diabetes of the Young, Type 3

Interventions

DRUG

Glimepiride 1Mg Tablet

Glimepiride

DRUG

Glucagon-like Peptide-1

GLP-1 infusion

DRUG

Glucose-Dependent Insulinotropic Polypeptide

GIP-infusion

DRUG

Placebo Oral Tablet

Placebo

DRUG

Placebo infusion

Placebo (saline)

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-08
Primary Completion
2018-06-01
Completion
2018-06-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03081676 on ClinicalTrials.gov